ICYMI: Top Content From AMCP Annual Meeting
Among the conference highlights from the annual meeting of the Academy of Managed Care Pharmacy (AMCP) were an interview on chimeric antigen receptor T-cell therapies and a session on best practices for value-based contracting.
Machine Learning Can Identify Patients With HF at Risk for Wild-Type ATTR-CM Earlier
Delayed diagnosis of wild-type transthyretin amyloid cardiomyopathy (ATTR-CM) results in inappropriate treatments prior to diagnosis and worse clinical outcomes after diagnosis.
Formulary Placement Led to Delays, Disruptions in Receiving Sacubitril/Valsartan for CHF
More than a quarter of patients experience disruptions and delays in treatment for chronic heart failure (CHF) after the initial prescription for sacubitril/valsartan was abandoned/rejected.
Mayo Clinic Saves $23M Through Biosimilar Adoption Program
Implementing changes in a health system to promote biosimilar adoption is not easy, but by implementing a program, there could be substantial savings.
CAR T Offers Clinical Hope but Reimbursement, Access Hurdles Remain
The clinical effectiveness of chimeric antigen receptor (CAR) T-cell therapies adds a new weapon in the arsenal to treat patients with relapsed and refractory disease; however, they come with access, logistical, and reimbursement challenges that make it difficult to treat all the patients who could benefit.
What Dr Zahra Mahmoudjafari Wishes Payers Knew About CAR T-Cell Therapies
Zahra Mahmoudjafari, PharmD, BCOP, clinical pharmacy manager at the University of Kansas Health System, gives her take on what payers should keep in mind when dealing with chimeric antigen receptor (CAR) T-cell therapies.
Identifying Best Practices for Successful Value-Based Contracting
Value-based contracts are growing as drugs get more expensive and effective, but it’s still an emerging area with a lot of unknown and uncertainty.
Katie Lockhart Details How the Specialty Drug Pipeline Is Expected to Affect Payers
Pipeline forecasting can provide payers better insight into which expensive specialty drugs coming down the pipeline they should be keeping their eyes on, according to Katie Lockhart, MA, manager at Magellan Health.
Dr Chelsee Jensen Explains Implementing Biosimilars in Small vs Large Practices
Chelsee Jensen, PharmD, pharmaceutical formulary manager at Mayo Clinic, explains how the process of implementing biosimilars may differ depending on practice size.
Dr Soumya Vishwanath Gives an Overview of the Therapeutic Gaps in Behavioral Health Disorders
Soumya Vishwanath, PharmD, senior manager of formulary strategy at
Magellan Rx Management, highlighted the therapeutic gaps that need to be addressed to ensure that patients with behavioral health disorders are well cared for.
Upcoming Generics Provide New Considerations and Opportunities for Savings
In 2022 and 2023, there are a number of big therapies losing patent exclusivity, which opens the door to generics that could save as much as $30 billion.
Trends and Drug Launches Impacting the US Health Care Market in 2021-2022
While the pandemic will have lasting impacts on the US health care market, much of it has bounced back and returned to normal, said Doug Long, MBA, of IQVIA, during the Thursday keynote at the Academy of Managed Care Pharmacy annual meeting.
Medication Therapy Management in TennCare Medicaid Shows Promise in Pilot Study
Although the medication therapy management program in Tennessee's Medicaid population did not reduce costs, some adherence to medication improved and emergency department visits improved.
Jeffrey Casberg Highlights Regulatory, Legal Barriers That Impact Drug Launch Dates
Jeffrey Casberg, vice president of pharmacy at IPD Analytics, discussed some of the regulatory and legal hurdles that generic and biosimilar companies have to face on the road to market launch.
Severe Uncontrolled Asthma Results in Higher Economic Burden Despite Treatment With Biologics
Patients with severe asthma continue to have residual disease despite initiating treatment with biologics, and severe uncontrolled asthma is associated with higher economic burden compared with controlled asthma, according to 2 posters.
Utilizing Data, Partnerships Can Address Racial and Ethnic Health Disparities
Racial and ethnic health disparities are documented and substantial, but the data are out there to create programs that successfully address these disparities, said panelists.
Michael Ciarametaro Talks About Balancing Drug Price Reform With Encouraging Innovation
Michael Ciarametaro, MBA, vice president of research at the National Pharmaceutical Council, discusses the balance between lowering drug prices and encouraging innovation in new drug classes for serious diseases.
Melissa Andel Previews Her Upcoming Session on Drug Pricing Reform at AMCP 2022
Melissa Andel, principal at CommonHealth Solutions, previewed her session on policy making and pricing reform at the upcoming Academy of Managed Care Pharmacy's annual meeting.
Data, Disparities, Drug Pricing Take Center Stage at AMCP 2022
The annual spring meeting of AMCP 2022 will include keynote sessions on health care and marketplace trends and the specialty pharmaceutical pipeline, with a featured preconference session on bias in health care.
Real-world Data From Multiple Sources May Be Needed to Conduct Biosimilar Comparison Studies
Administrative claims data in oncology often lack sufficient information to conduct postmarketing comparison studies of biosimilars with their reference product, suggesting that other sources are needed to answer critical research questions.
For 2021, Cell, Gene Therapies Make Prime's “Drugs to Watch” List
Three cell and gene therapies were among the drugs included in a specialty drugs pipeline forecast at the Academy of Managed Care Pharmacy 2021 meeting.
Kaiser Permanente Researchers Review Regulatory Barriers to US Biosimilar Uptake
Changes to naming conventions and interchangeability labels are just some of the regulatory barriers standing in the way of biosimilar uptake, according to Kaiser Permanente researchers.
Avalere Analyst Reviews Future Change in Cancer Care Using Gene, Cell Therapies
Megan Olsen, MPH, principal at Avalere, discussed how gene and cell therapies can offer new treatment options for patients with cancer.
What’s Next in Health Policy After the First 100 Days of the Biden Presidency?
With President Joe Biden marking his 100th day in office at the end of the month, a health policy strategist sat down for a conversation to discuss the new administration’s achievements and challenges.
Drs Rebecca Borgert and Jim Rebello Discuss What Could Persuade Payers to Use Biosimilars
Rebecca Borgert, PharmD, BCOP, and Jim Rebello, PharmD, from Magellan Rx Management, discussed what evidence they believe could persuade payers to include biosimilars as preferred formulary products.
Low-Income, Non-White Patients Delay Care Using HDHPs, Study Says
A poster at the Academy of Managed Care Pharmacy 2021 meeting examined the impact of high-deductible health plans (HDHPs) on access to health care and resource use in the United States and the interaction of race, ethnicity, and income.
BCBS Researchers Discuss CMS’ 2021 Changes to Medicare Star Rating Criteria
Karen Coderre, PharmD, and Madhavi Manduru-Rao, PharmD, detail how CMS' increased weighting for Consumer Assessment of Health Care Providers and Systems surveys impacts Star ratings.
COVID-19’s Impact on Marketplace Trends Will Continue, but Lessen
The pandemic reduced visits to specialists last year, which in turn reduced the volume of prescriptions, according to a presentation at the Academy of Managed Care Pharmacy 2021 meeting.
How Can Medicare Part D Keep Up With a More Complex, Costly Landscape?
Compared with when Medicare Part D launched, therapies today are more expensive. A panel at the Academy of Managed Care Pharmacy 2021 meeting discussed how the benefit needs to adapt to keep up with the future.
Brenden O’Hara Discusses the Importance of Collaboration in Value-Based Contracts
Brenden O’Hara, RPh, BCACP, from Blue Cross Blue Shield of North Carolina, talked about the pharmacist’s role in improving outcomes in value-based contracts and why collaboration is needed.
2 Clarke Drive Cranbury, NJ 08512